Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FTY720-derivatives do not induce FTY720-like lymphopenia.

Ismael Segura-Ulate1, Troy K Belcher1, Guadalupe Vidal-Martinez1

  • 1Department of Biomedical Sciences, Graduate School of Biomedical Sciences, Center of Emphasis in Neurosciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.

Journal of Pharmacological Sciences
|April 2, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory study of the dysregulation of age-related changes in neural/glial antigen 2 and neuroinflammation markers in individuals with major depression.

Brain, behavior, & immunity - health·2025
Same author

The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors.

Journal of Alzheimer's disease : JAD·2024
Same author

Cross comparison of alternative diagnostic protocols including substitution to the clinical sample, RNA extraction method and nucleic acid amplification technology for COVID-19 diagnosis.

Frontiers in molecular biosciences·2024
Same author

Latin American Trans-ancestry INitiative for OCD genomics (LATINO): Study protocol.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics·2023
Same author

Development of an instrument-free and low-cost ELISA dot-blot test to detect antibodies against SARS-CoV-2.

Open life sciences·2023
Same author

Latin American Trans-ancestry INitiative for OCD genomics (LATINO): Study Protocol.

medRxiv : the preprint server for health sciences·2023
Same journal

Differentiation of human-induced pluripotent stem cells into hepatocytes-like cells in 3D culture using functional polymers.

Journal of pharmacological sciences·2026
Same journal

Rice-memolin modulates prefrontal neural oscillations during sleep.

Journal of pharmacological sciences·2026
Same journal

Inhibition of ceramide synthase 5 ameliorates pulmonary fibrosis via suppression of TGF-β/Smad signaling.

Journal of pharmacological sciences·2026
Same journal

Luzindole and ramelteon share a melatonin receptor-independent blocking effect on voltage-gated potassium K<sub>V</sub>4.2 channels.

Journal of pharmacological sciences·2026
Same journal

Glyoxal fixation is applicable to whole-brain serial section imaging in mice.

Journal of pharmacological sciences·2026
Same journal

Dendrobine alleviates lung injury in septic mice by inhibiting mitochondrial-endoplasmic reticulum crosstalk-mediated NLRP3 inflammasome activation.

Journal of pharmacological sciences·2026
See all related articles

New FTY720 derivatives show potential for Parkinson's disease therapy by stimulating neuroprotection without immunosuppression. These compounds may offer a safer alternative for treating Parkinson's patients.

Area of Science:

  • Neuroscience and Pharmacology
  • Immunology

Background:

  • FTY720, an immunosuppressive drug for multiple sclerosis (MS), enhances neuroprotective brain-derived-neurotrophic-factor (BDNF) expression.
  • Preclinical studies suggest FTY720's potential in Parkinson's disease (PD) treatment, but its immunosuppressive properties pose a limitation.

Purpose of the Study:

  • To evaluate novel FTY720 derivatives (FTY720-C2 and FTY720-Mitoxy) as potential Parkinson's disease therapies.
  • To assess if these derivatives stimulate BDNF expression and brain penetration without causing immunosuppression.

Main Methods:

  • Administration of low and high doses of FTY720 derivatives to preclinical models.
  • Assessment of lymphopenia and immunosuppressive signaling, using FTY720 as a positive control.
Keywords:
Anti-inflammatoryFingolimodNeuroprotection

Related Experiment Videos

Main Results:

  • FTY720 derivatives stimulate BDNF expression and exhibit brain penetration, similar to FTY720.
  • Unlike FTY720, the derivatives were not phosphorylated and did not induce FTY720-like lymphopenia or immunosuppression.

Conclusions:

  • The novel FTY720 derivatives demonstrate neuroprotective potential without the immunosuppressive side effects of FTY720.
  • These findings support further preclinical investigation of FTY720-C2 and FTY720-Mitoxy as promising therapeutic candidates for Parkinson's disease.